11 apr: Europa/luk: Nådesløs afstraffelse af Nokia
12 apr: Selskabernes forventninger - torsdag den 12 april
11-04-2012 23:21:00

Quest Diagnostics Names Rusckowski As President, CEO

Relateret indhold

DOW JONES NEWSWIRES

Quest Diagnostics Inc. (DGX) named Royal Philips Electronics NV (PHG, PHIA.AE) executive Stephen Rusckowski as its new president and chief executive, ending a six-month search for a successor to current CEO Surya Mohapatra.

Rusckowski's appointment is effective May 1 and he will also join the company's board. Rusckowski has served as CEO of Philips Healthcare, Royal Philips' largest unit, since 2006.

The management change could mark a new course for the company. Some decisions Quest made under Mohapatra--such as the acquisition of diagnostics company AmeriPath Inc. and an expansion into India--have been criticized by analysts.

Quest, the largest diagnostic-testing company in the U.S. by revenue, had been hurt by a decline in doctor-office visits as consumers have reined in their health-care spending since the recession. Last year, the company unveiled a restructuring initiative to reduce its costs by $500 million over the next three years to help it meet profit targets. In October, the company initiated a search for a replacement for Mohapatra, who held the titles of chairman, president and CEO.

Quest also appointed lead director Daniel C. Stanzione as its new non-executive chairman.

"Steve Rusckowski is uniquely qualified to be chief executive officer of Quest Diagnostics," Stanzione said. "He has built an enviable track record in health care by successfully driving growth, both organically and through disciplined, effective acquisitions. His emphasis on operational excellence has enabled him to deliver consistently impressive results."

In January, Quest reported its fourth-quarter earnings rose 14% as the company saw higher testing revenue and improved margins.

Shares closed at $59.57 Wednesday and were unchanged after hours. The stock is up 2.6% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

(END) Dow Jones Newswires

April 11, 2012 17:21 ET (21:21 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Genmab fortsætter rekordridt på grøn dag

24-05-2016 11:41:24
De danske aktier er efter en lavere start kommet i bedre form ud på formiddagen tirsdag og ligger kort før middag med små plusser.Blandt eliteaktierne trækker b..

Aktier/tendens: Udsigt til let vigende aktier efter fald i USA

24-05-2016 08:13:54
Pilen ser ud til at ville pege en smule ned for det danske aktiemarked tirsdag morgen, hvor en lille håndfuld mindre selskaber er klar med regnskaber for første..

Arkil-konsortium taber kontrakt hos Banedanmark

23-05-2016 15:29:01
Banedanmark har mandag ophævet kontrakten med konsortiet Strukton Rail om sporombygningsarbejde på Østfyn efter problemerne med togdriften i Kristi himmelfarts-..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab får kræfthåb godkendt i Europa - NY
2
Bavarian opnår positive resultater med vaccine mod RS-virus -NY
3
Vestas-dir: Innovation eller vi dør
4
Arkil-aktien røg af sporet
5
Mandagens aktier: Genmab sprintede fra C20-feltet

Relaterede aktiekurser

Philips KON 23,21 0,7% Stigning i aktiekurs
Koninklijke Philips N.V. 25,76 0,0% Aktiekurs uændret
Quest Diagnostics Inc 76,10 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2016 13:51:53
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160517.1 - EUROWEB1 - 2016-05-24 13:51:53 - 2016-05-24 13:51:53 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x